Can CSF biomarkers predict future MS disease activity and severity? Tuesday, April 27, 2021 Multiple sclerosis (MS) is a heterogeneous disease. With several disease modifying treatments of different mechanisms of action in use now and in development, it is important to identify reliable biomarkers to identify those higher risk MS patients in whom stronger but riskier treatments might be used, as well as to identify those for whom safer treatments of lower efficacy would be sufficient. Read More
The Foundation Welcomes New Board Members Friday, April 02, 2021 The Foundation is very pleased to welcome six new board members in 2021. You can read more about the first three here. Read More